Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represent a cornerstone in the treatment of diabetes and obesity and have emerged as a promising option for other metabolic disorders, including hepatic steatosis. This evidence concerns the gene GCG and Other metabolic disease.